-

Simulations Plus to Present at the LD 500 Virtual Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will be presenting at the LD 500 Virtual Conference on Wednesday, September 2, 2020, at 1:40 p.m. ET / 10:40 a.m. PT.

The presentation will be webcast live, and you may register for the Company’s presentation here. The slide presentation will be available in the Resource Center of the Simulations Plus website following the presentation. For more information about the conference, please contact Hayden IR at slp@haydenir.com.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of drug discovery/development software and a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury, drug-induced kidney injury, and nonalcoholic fatty liver disease. Our software is used to conduct drug research by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading provider for physiologically based pharmacokinetic modeling and simulation. Visit us online www.simulations-plus.com.

Follow us on Twitter | LinkedIn | YouTube

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee@simulations-plus.com

Hayden IR
Mr. Cameron Donahue
651-653-1854
slp@haydenir.com

Simulations Plus, Inc.

NASDAQ:SLP

Release Summary
Simulations Plus today announced that chief executive officer Shawn O'Connor will present at LD Micro's LD 500 Virtual Conference on Sept. 2, 2020.
Release Versions

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee@simulations-plus.com

Hayden IR
Mr. Cameron Donahue
651-653-1854
slp@haydenir.com

Social Media Profiles
More News From Simulations Plus, Inc.

Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that experimental results of its artificial intelligence-driven drug design (AIDD) collaboration with the Institute of Medical Biology of the Polish Academy of Sciences (IMB PAS) have been published in the Amer...

Simulations Plus Invests in Clinical Development Technology Company Nurocor

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor. Founded in 2017, Nurocor offers a cloud-based software platform designed to improve efficiency, reusability, governance, and automation for pharmaceuti...

Simulations Plus Releases ADMET Predictor® 13

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13...
Back to Newsroom